Interleukin-6 and CAAT/enhancer binding protein β-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation

Immunobiology

Volumn 198, Issue 1-3, 1997, Pages 144-156

  Alonzi, Tonino ^a,d   Gorgoni, Barbara ^a,d   Screpanti, Isabella ^b   Gulino, Alberto ^c   Poli, Valeria ^a,d  

^a IRBM   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; STAT3 PROTEIN;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; IMMUNE DEFICIENCY; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031449469     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(97)80035-6     Document Type: Article

References (28)

1. HIRANO, T., S. AKIRA, T. TAGA, and T. KISHIMOTO. 1990. Biological and clinical aspects of interleukin 6. Immunol. Today 11:443.
2. KAWANO, M. M., K. MIHARA, N. HUANG, T. TSUJIMOTO, and A. KURAMOTO. 1995. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85: 487.
3. KISHIMOTO, T., S. AKIRA, M. NARAZAKI, and T. TAGA. 1995. Interleukin-6 family of cytokines and gp130. Blood 86: 1243.
4. AKIRA, S., Y. NISHIO, M. INOUE, X. J. WANG, S. WEI, T. MATSUSAKA, K. YOSHIDA, T. SUDO, M. NARUTO, and T. KISHIMOTO. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signalling pathway. Cell 77: 63.
5. POLI, V., F. P. MANCINI, and R. CORTESE. 1990. IL6-DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell 63: 643.
6. LAI, C. F., J. RIPPERGER, K. K. MORELLA, Y. WANG, D. P. GEARING, G. H. FEY, and H. BAUMANN. 1995. Separate signaling mechanisms are involved in the control of Stat protein activation and gene regulation via the interleukin 6 response element by the box 3 motif of gp130. J. Biol. Chem. 270: 14847.
7. POLI, V. and G. CILIBERTO. Transcriptional regulation of acute phase genes by IL-6 and related cytokines. In Tronche F., and M. Yaniv. 1994. Liver gene expression, R. G. Landes Company Biomedical Publ., Austin, USA, 350 pp.
8. AKIRA, S., H. ISSIHIKI, T. SUGITA, O. TANABE, S. KINOSHITA, Y. NISHIO, T. NAKAJIMA, T. HIRANO, and T. KISHIMOTO. 1990. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 9: 1897.
9. CAPPELLETTI, M., T. ALONZI, E. FATTORI, C. LIBERT, and V. POLI. 1996. C/EBPβ is required for the late phases of acute phase genes induction in the liver and for tumor necrosis factor-α, but not interleukin-6, regulation. Cell Death & Differentiation 3: 29.
10. SCHINDLER, C. and J. E. JR. DARNELL. 1995. Transcriptional responses to polypeptide ligands: the Jak-Stat pathway Annu. Rev. Biochem. 64: 621.
11. KOPF, M., H. BAUMANN, G. FREER, M. FREUDENBERG, M. LAMERS, T. KISHIMOTO, R. ZINKERNAGEL, H. BLUETHMANN, and G. KOHLER. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339.
12. POLI, V., R. BALENA, E. FATTORI, A. MARKATOS, M. YAMAMOTO, H. TANAKA, G. CILIBERTO, G. A. RODAN, and F. COSTANTINI. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13: 1189.
13. SCREPANTI, I., L. ROMANI, P. MUSIANI, A. MODESTI, E. FATTORI, D. LAZZARO, C. SELLITTO, S. SCARPA, D. BELLAVIA, G. LATTANZIO, F. BISTONI, L. FRATI, R. CORTESE, A. GULINO, G. CILIBERTO, F. COSTANTINI, and V. POLI. 1995. Lymphoproliferative disorder and imbalanced T-helper response in C/EBPβ-deficient mice. EMBO J. 14: 1932.
14. TANAKA, T., S. AKIRA, K. YOSHIDA, M. UMEMOTO, Y. YONEDA, N. SHIRAFUJI, H. FUJIWARA, S. SUEMATSU, N. YOSHIDA, and T. KISHIMOTO. 1995. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80: 353.
15. SCREPANTI, I., P. MUSIANI, D. BELLAVIA, M. CAPPELLETTI, F. B. AIELLO, M. MARODER, L. FRATI, A. MODESTI, A. GULINO, and V. POLI. 1996. Inactivation of the IL-6 gene prevents development of multicentric Castelman's disease in C/EBPβ-deficient mice. J. Exp. Med. 184: 1561.
16. ARCONE, R., P. PUCCI, F. ZAPPACOSTA, V. FONTAINE, A. MALORNI, G. MARINO, and G. CILIBERTO. 1991. Single-step purification and structural characterisation of human interleukin-6 produced in Escherichia coli from a T7 RNA polymerase expression vector. Eur. J. Biochem. 198: 541.
17. GORSKI, K., M. CARNEIRO, and U. SCHIBLER. 1986. Tissue-specific in vitro transcription from the mouse albumin promoter. Cell 47: 767.
18. ZHONG, Z., Z. WEN, and J. E. DARNELL. 1994. Stat3: a Stat family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95.
19. FATTORI, E., M. CAPPELLETTI, P. COSTA, C. SELLITTO, L. CANTONI, M. CARELLI, R. FAGGIONI, G. FANTUZZI, P. GHEZZI, and V. POLI. 1994. Defective inflammatory response in Interleukin-6-deficient mice. J. Exp. Med. 180: 1243.
20. VAN SNICK, J., S. CAYPHAS, A. VINK, C. UYTTENHOVE, P. G. COULIE, M. R. RUBIRA, and R. J. SIMPSON. 1986. Purification and NH2-terminal aminoacid sequence of a T-cell derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. USA. 83: 9679.
21. AGGARWAL, B. B., W. J. KOHR, P. E. HASS, B. MOFFAT, S. A. SPENCER, W. J. HENZEL, T. S. BRINGMAN, G. E. NEDWIN, D. V. GOEDDEL, and R. N. HARKINS. 1985. Human tumor necrosis factor: production, purification and characterization. J. Biol. Chem. 260: 2345.
22. SADOWSKI, H. B., K. SHUAI, J. E. DARNELL, and M. Z. GILMAN. 1993. A common nuclear signal tran'sduction pathway activated by growth factor and cytokine receptors. Science 261: 1739.
23. WARING, P. M., L. J. WARING, T. BILLINGTON, and D. METCALF. 1995. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. Proc. Natl. Acad. Sci. USA 92: 1337.
24. PETERSON, B. A., and G. FRIZZERA. 1993. Multicentric Castleman's disease. Sem. Oncol. 20: 636.
25. YOSHIZAKI, K., T. MATSUDA, N. NISHIMOTO, T. KURITANI, L. TAEHO, K. AOZASA, T. NAKAHATA, K. KAWAI, H. TAGOH, T. KOMORI, S. KISHIMOTO, T. HIRANO, and T. KISHIMOTO. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360.
26. BRANDT, S. J., D. M. BODINE, C. E. DUNBAR, and A. W. NIENHUIS. 1990. Disregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86: 592.
27. BECK, J. T., S. M. HSU, J. WIJDENESS, R. BATAILLE, B. KLEIN, D. VESOLE, K. HAYDEN, S. JAGANNATH, and B. BARLOGIE. 1994. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. New Engl. J. Med. 330: 602.
28. ALONZI, T., E. FATTORI, M. CAPPELLETTI, G. CILIBERTO, and V. POLI. 1997. Impaired Stat3 activation following localized inflammatory stimulus in IL-6-deficient mice. Cytokine. In press.